Publications
Selected scientific literature on SPT and the role of ceramides and sphingolipids in Parkinson’s disease.
Inhibition of de novo ceramide synthesis mitigates alpha-synuclein pathology in a Parkinson’s disease mouse model
Lee E, et al.
npj Parkinson’s Disease 12, 49, 2026
1-Deoxysphingolipids require very-long-chain ceramide synthesis to induce ER stress and cytotoxicity
Byrnes C, et al.
Journal of Biological Chemistry 302, 113281, 2026
The riddle of sphingolipid structure-function relationship in the nervous system
Muñoz-Gil S, et al.
Journal of Biological Chemistry 302, 113258, 2026
Serine palmitoyltransferase (SPT) inhibition in SPTSSA-related complex hereditary spastic paraplegia
Gong Y, et al.
JCI Insight, e206228, 2026
1-Deoxysphingolipids dysregulate membrane properties and cargo trafficking in the early secretory pathway
Tsai Y-T, et al.
Cell Chemical Biology 33, 45–58, 2026
Dysregulated metabolism of ceramides and glycosphingolipids in Parkinson’s disease
Peng Y-F, et al.
Journal of Lipid Research 67, 100955, 2026
Mapping the causal chain from genetic risk variants to lipid dysmetabolism in Parkinson’s disease
De-Paula RB, et al.
medRxiv (preprint), 2025
The sphingolipids clearly play a role in Parkinson’s disease, but nature has made it complicated
Lansbury PT.
Movement Disorders 37, 1985–1989, 2022
Inhibition of ceramide synthesis reduces α-synuclein proteinopathy in a cellular model of Parkinson’s disease
Mingione A, et al.
International Journal of Molecular Sciences 22, 6469, 2021
Neurodegenerative disorders: spotlight on sphingolipids
Mandik F, Vos M.
International Journal of Molecular Sciences 22, 11998, 2021
Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies
Nalls MA, et al.
Lancet Neurology 18, 1091–1102, 2019
1-Deoxysphingolipids
Lone MA, et al.
Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids 1864, 512–521, 2019
CTP-692: Selective deuterium modification of D-serine markedly decreases renal toxicity in preclinical testing
Brummel et al.
Poster, American College of Toxicology 39th Annual Meeting, West Palm Beach, FL, November 4–7, 2018
D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson’s disease
Gelfin E, et al.
International Journal of Neuropsychopharmacology 15, 543–549, 2012
Interested in learning more about CeraLink?
We welcome conversations with potential partners, investors, and collaborators who share our commitment to advancing new treatments for neurodegenerative disease.